

#### Phospho-ZAP70(Y292) Antibody Blocking peptide Synthetic peptide Catalog # BP3676a

### Specification

# Phospho-ZAP70(Y292) Antibody Blocking peptide - Product Information

Primary Accession

#### <u>P43403</u>

## Phospho-ZAP70(Y292) Antibody Blocking peptide - Additional Information

Gene ID 7535

**Other Names** 

Tyrosine-protein kinase ZAP-70, 70 kDa zeta-chain associated protein, Syk-related tyrosine kinase, ZAP70, SRK

Target/Specificity

The synthetic peptide sequence used to generate the antibody <a href=/products/AP3676a>AP3676a</a> was selected from the region of human Phospho-ZAP70-Y292. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

## **Storage** Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions** This product is for research use only. Not for use in diagnostic or therapeutic procedures.

# Phospho-ZAP70(Y292) Antibody Blocking peptide - Protein Information

Name ZAP70

Synonyms SRK

#### Function

Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates motility, adhesion and cytokine expression of mature T-cells, as well as thymocyte development. Contributes also to the development and activation of primary B- lymphocytes. When antigen presenting cells (APC) activate T-cell receptor (TCR), a serie of phosphorylations lead to the recruitment of ZAP70 to the doubly phosphorylated TCR component CD247/CD3Z through ITAM motif at the plasma membrane. This recruitment serves to localization to the stimulated TCR and to relieve its autoinhibited conformation. Release of ZAP70 active conformation is further stabilized by phosphorylation mediated by LCK. Subsequently, ZAP70 phosphorylates at least 2 essential adapter proteins: LAT and LCP2. In turn, a large number of



signaling molecules are recruited and ultimately lead to lymphokine production, T-cell proliferation and differentiation. Furthermore, ZAP70 controls cytoskeleton modifications, adhesion and mobility of T-lymphocytes, thus ensuring correct delivery of effectors to the APC. ZAP70 is also required for TCR-CD247/CD3Z internalization and degradation through interaction with the E3 ubiquitin-protein ligase CBL and adapter proteins SLA and SLA2. Thus, ZAP70 regulates both T-cell activation switch on and switch off by modulating TCR expression at the T-cell surface. During thymocyte development, ZAP70 promotes survival and cell-cycle progression of developing thymocytes before positive selection (when cells are still CD4/CD8 double negative). Additionally, ZAP70-dependent signaling pathway may also contribute to primary B-cells formation and activation through B-cell receptor (BCR).

#### **Cellular Location**

Cytoplasm. Cell membrane; Peripheral membrane protein. Note=In quiescent T-lymphocytes, it is cytoplasmic. Upon TCR activation, it is recruited at the plasma membrane by interacting with CD247/CD3Z. Colocalizes together with RHOH in the immunological synapse. RHOH is required for its proper localization to the cell membrane and cytoskeleton fractions in the thymocytes (By similarity).

#### **Tissue Location**

Expressed in T- and natural killer cells. Also present in early thymocytes and pro/pre B-cells

# Phospho-ZAP70(Y292) Antibody Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

#### <u>Blocking Peptides</u>

#### Phospho-ZAP70(Y292) Antibody Blocking peptide - Images

### Phospho-ZAP70(Y292) Antibody Blocking peptide - Background

ZAP70, a 70 kDa member of the Syk tyrosine kinase family, plays a central role in lymphocyte activation and development, and is implicated in several immune disorders. Mutations in ZAP70 gene results in a form of Severe Combined Immunodeficiency Syndrome (SCID) in humans. ZAP70 expression also defines a subset of Chronic Lymphocytic Leukemia (CLL) in patients with unmutated lg gene and poor clinical course.

### Phospho-ZAP70(Y292) Antibody Blocking peptide - References

Roberts,K.E., et.al., Gastroenterology (2010) In pressPapageorgis,P., et.al., Cancer Res. 70 (3), 968-978 (2010)